购物车 
-
对乙酰氨基苯酚
NMR and HPLC COA下载 MSDS下载 - Names：
4-Acetamidophenol
- CAS号：
103-90-2
MDL Number： MFCD00002328 - MF(分子式)： C8H9NO2 MW(分子量)： 151.16
- EINECS:203-157-5 Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
对乙酰氨基苯酚(103-90-2,4-Acetamidophenol)为白色结晶或结晶性粉末，熔点168～172℃，无臭，味微苦，对乙酰氨基苯酚在热水或乙醇中易溶，在丙酮中溶解，几乎不溶于冷水和石油醚。对乙酰氨基苯酚在45℃以下稳定，但如果暴露在潮湿的空气中会水解成对氨基酚，然后进一步发生氧化，颜色逐渐变成粉红色、棕色，最后成黑色，因此应在阴冷干燥处密闭保存。
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM002976-5g | 5g | 99.6% | ¥ 405.00 | ¥ 405.00 | 2-3天 | ¥ 0.00 | ||
| YZM002976-500mg | 500mg | 99.6% | ¥ 292.00 | ¥ 292.00 | 2-3天 | ¥ 0.00 | ||
| JT24018-25g | 25g | 98% | ¥ 50.00 | ¥ 50.00 | 36 | Instock,1days | ¥ 0.00 | |
| JT24018-500g | 500g | 98% | ¥ 344.00 | ¥ 344.00 | 255 | Instock 1days | ¥ 0.00 | |
| JT24018-100g | 100g | 98% | ¥ 106.00 | ¥ 106.00 | 77 | Instock,1days | ¥ 0.00 | |
| HCM93600-1g | 1g | 95% | ¥ 0.00 | ¥ 0.00 | 1-2days | ¥ 0.00 |
| 中文别名 | 对乙酰氨基苯酚(103-90-2,4-Acetamidophenol),4'-羟基乙酰苯胺;4-乙酰胺基苯酚;N-(4-羟基苯基)乙酰胺;乙醯胺酚;对乙酰氨基苯酚;对羟基乙酰苯胺;4-乙酰氨基酚;N-乙酰对氨基酚;扑热息痛 |
| 英文别名 | 4-Acetamidophenol(103-90-2),acetaminophen,Paracetamol,N-(4-Hydroxyphenyl)acetamide |
| CAS号 | 103-90-2 |
| Inchi | InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10) |
| InchiKey | RZVAJINKPMORJF-UHFFFAOYSA-N |
| 分子式 Molecular Weight | C8H9NO2 |
| 分子量 Formula | 151.16 |
| 溶解度Solubility | 溶于水(14 g/l at 20 °C), 乙醇 (100 mM), 二甲基亚砜(100 mM), 甲醇(50 mg/ml), and 二甲基甲酰胺. |
| 性状 | 白色结晶或结晶性粉末 |
| 储藏条件 Storage conditions | 在-20°C条件下保存3年,在4°C条件下保存2年 |
对乙酰氨基苯酚(103-90-2,4-Acetamidophenol)的毒性测试:
| 生物 | 测试类型 | 路线 | 报告剂量（标准化剂量） | 影响 | 参考 |
|---|---|---|---|---|---|
| child | LDLo | oral | 50mg/kg (50mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA CARDIAC: OTHER CHANGES |
American Journal of Emergency Medicine. Vol. 6, Pg. 510, 1988. |
| child | LDLo | oral | 140mg/kg/7D-I (140mg/kg) | BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)" BEHAVIORAL: COMA LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), ZONAL" |
Medical Journal of Australia. Vol. 171, Pg. 472, 1999. |
| child | LDLo | oral | 360mg/kg/2D (360mg/kg) | LIVER: OTHER CHANGES SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" GASTROINTESTINAL: NAUSEA OR VOMITING |
Journal of Pediatrics. Vol. 92, Pg. 832, 1978. |
| child | TDLo | oral | 591mg/kg/2D-I (591mg/kg) | BLOOD: APLASTIC ANEMIA LIVER: LIVER FUNCTION TESTS IMPAIRED KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" |
Clinical Pediatrics Vol. 33, Pg. 42, 1994. |
| child | TDLo | oral | 801mg/kg (801mg/kg) | LIVER: OTHER CHANGES GASTROINTESTINAL: NAUSEA OR VOMITING BEHAVIORAL: GENERAL ANESTHETIC |
Pediatrics. Vol. 61, Pg. 68, 1978. |
| dog | LDLo | intravenous | 826mg/kg (826mg/kg) | BEHAVIORAL: ANALGESIA | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 149, Pg. 571, 1964. |
| dog | LDLo | oral | 2gm/kg (2000mg/kg) | BLOOD: CHANGES IN SPLEEN BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) |
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 24, Pg. 602, 1993. |
| frog | LDLo | subcutaneous | 50mg/kg (50mg/kg) | BEHAVIORAL: ATAXIA BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES |
Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 33, Pg. 216, 1894. |
| guinea pig | LD50 | oral | 2620mg/kg (2620mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: TREMOR |
Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 47, Pg. 479, 1958. |
| human | LDLo | oral | 143mg/kg (143mg/kg) | BEHAVIORAL: GENERAL ANESTHETIC | British Medical Journal. Vol. 282, Pg. 199, 1981. |
| human | LDLo | oral | 357mg/kg (357mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING BEHAVIORAL: ANOREXIA (HUMAN BEHAVIORAL: COMA |
Lancet. Vol. 1, Pg. 66, 1973. |
| infant | TDLo | oral | 1440mg/kg/6D (1440mg/kg) | American Journal of Diseases of Children. Vol. 137, Pg. 386, 1983. | |
| infant | TDLo | oral | 1440mg/kg/6D (1440mg/kg) | BEHAVIORAL: IRRITABILITY GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" |
American Journal of Diseases of Children. Vol. 137, Pg. 386, 1983. |
| mammal (species unspecified) | LD50 | unreported | 891mg/kg (891mg/kg) | Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 48(6), Pg. 22, 1983. | |
| mammal (species unspecified) | LDLo | oral | 512mg/kg (512mg/kg) | United States Patent Document. Vol. #4035499, | |
| man | LDLo | oral | 143mg/kg/24H- (143mg/kg) | BEHAVIORAL: ANOREXIA (HUMAN LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), ZONAL" LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED" |
American Journal of Medicine. Vol. 74, Pg. 349, 1983. |
| man | LDLo | oral | 714mg/kg (714mg/kg) | LIVER: OTHER CHANGES | Human Toxicology. Vol. 1, Pg. 25, 1981. |
| man | TDLo | oral | 9286ug/kg (9.286mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" SENSE ORGANS AND SPECIAL SENSES: OTHER: EAR |
Allergy. Vol. 50(Suppl, |
| man | TDLo | oral | 714mg/kg (714mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE | Postgraduate Medical Journal. Vol. 69, Pg. 52, 1993. |
| mouse | LD50 | intraperitoneal | 367mg/kg (367mg/kg) | BEHAVIORAL: ANALGESIA | Arzneimittel-Forschung. Drug Research. Vol. 15, Pg. 520, 1965. |
| mouse | LD50 | oral | 338mg/kg (338mg/kg) | Toxicology and Applied Pharmacology. Vol. 19, Pg. 20, 1971. | |
| mouse | LD50 | subcutaneous | 310mg/kg (310mg/kg) | Human Toxicology. Vol. 3, Pg. 13S, 1984. | |
| pig | LDLo | intravenous | 1gm/kg (1000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES LIVER: OTHER CHANGES |
Veterinary and Human Toxicology. Vol. 30, Pg. 324, 1988. |
| rat | LD50 | intraperitoneal | 1205mg/kg (1205mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Studi Sassaresi, Sezione 2. Vol. 57, Pg. 561, 1979. |
| rat | LD50 | oral | 1944mg/kg (1944mg/kg) | United States Patent Document. Vol. #4636513, |
对乙酰氨基苯酚(103-90-2,4-Acetamidophenol)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品时尽量采用多个药勺分别使用，使用后清洗干净后，烘干消毒存放。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
4-Acetamidophenol(103-90-2) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:对乙酰氨基苯酚(103-90-2,4-Acetamidophenol),对乙酰氨基苯酚的作用,对乙酰氨基苯酚抑制剂,对乙酰氨基苯酚的纯度,对乙酰氨基苯酚的合成,对乙酰氨基苯酚的用途,对乙酰氨基苯酚的生产,对乙酰氨基苯酚的保存,对乙酰氨基苯酚的外观,对乙酰氨基苯酚的溶解度
| 产品说明 | 对乙酰氨基苯酚(103-90-2)是一种有效的肝 N-乙酰转移酶 2 (NAT2) 抑制剂,对乙酰氨基苯酚溶解度,对乙酰氨基苯酚MSDS,对乙酰氨基苯酚结构式详见主页. |
| Introduction | 4-Acetamidophenol(103-90-2,对乙酰氨基苯酚) is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor |
| Application1 | 有机合成中间体，过氧化氢的稳定剂，照相化学药品 |
| Application2 | 对乙酰氨基苯酚通过抑制下丘脑体温调节中枢前列腺素的合成，起解热的作用 |
| Application3 | 对乙酰氨基苯酚与氯霉素合用，可延长后者的t1/2，增强其毒性 |
Acetaminophen is a p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.
对乙酰氨基苯酚(103-90-2,4-Acetamidophenol)的合成方法：
1.以硝基苯为原料
在有浓硫酸和十六烷基三甲基氯化铵的条件下，以Pd/C为催化剂，将硝基苯催化氢化为对氨基酚。对氨基酚不经分离，直接乙酰化合成对乙酰氨基酚，收率64.3%。反应式如下：
2.以对硝基酚为原料
以对硝基酚为原料，Pd/C催化加氢酰化一步合成对乙酰氨基酚，最佳溶剂为醋酸，用量为对硝基酚的2～5倍，对乙酰氨基酚收率可达95%。将催化剂改为Pd-La/C后，对乙酰氨基酚收率达到97%。反应式如下：
3.以对氨基酚为原料
以对氨基苯酚和乙酸酐为原料，以锌粉为抗氧化剂，以活性炭为脱色剂，以稀乙酸为反应介质，采用微波辐射技术合成对乙酰氨基酚，产率可达81.2%。反应式如下：
4.以对羟基苯乙酮为原料
先将对羟基苯乙酮肟化，再经Beckmann重排制得对乙酰氨基酚。用此法将对羟基苯乙酮肟化后得对羟基苯乙酮肟，收率93.5%，然后用Hβ分子筛作为催化剂，以丙酮为溶剂，重排得对乙酰氨基酚，产率81.2%。以丙酮为重排反应溶剂，用Al-MCM-41分子筛作为重排反应催化剂，催化剂中磷酸含量30%时产率达最高值。反应式如下：
5.以苯酚为原料
以苯酚为原料，经乙酰化、Fries重排、肟化、Beckmann重排合成对乙酰氨基酚，收率分别为82%，68.6%，92.5%，50.5%。反应式如下：
| 警示图 | |
| 危险性 | warning |
| 危险性警示 | No data available |
| 安全声明 | H302,H315,H319,H335 |
| 安全防护 | P261,P305+P351+P338 |
| 备注 | 实验过程中防止吸入、食入，做好安全防护 |
| Reported ingested dose of paracetamol as a predictor of risk following paracetamol overdose |
| Transformation of acetaminophen during water chlorination treatment: kinetics and transformation products identification |
| Photocatalytic degradation of acetaminophen in modified TiO2 under visible irradiation |
| Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen |
| Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients |
1.Evaluation of Hepatoprotective Activity of Adansonia digitata Extract on Acetaminophen-Induced Hepatotoxicity in Rats.
Hanafy A1, Aldawsari HM2, Badr JM3, Ibrahim AK4, Abdel-Hady Sel-S2. Evid Based Complement Alternat Med. 2016;2016:4579149. doi: 10.1155/2016/4579149. Epub 2016 Mar 16.
Abstract：The methanol extract of the fruit pulp of Adansonia digitata L. (Malvaceae) was examined for its hepatoprotective activity against liver damage induced by acetaminophen in rats. The principle depends on the fact that administration of acetaminophen will be associated with development of oxidative stress. In addition, hepatospecific serum markers will be disturbed. Treatment of the rats with the methanol extract of the fruit pulp of Adansonia digitata L. prior to administration of acetaminophen significantly reduced the disturbance in liver function. Liver functions were measured by assessment of total protein, total bilirubin, ALP, ALT, and AST. Oxidative stress parameter and antioxidant markers were also evaluated. Moreover, histopathological evaluation was performed in order to assess liver case regarding inflammatory infiltration or necrosis. Animals were observed for any symptoms of toxicity after administration of extract of the fruit pulp of Adansonia digitata L.
2.Retrospective Evaluation of a Fixed-Dose Combination of Oxycodone and Acetaminophen to Manage Moderate Pain: The Lower the Better.
Natoli S1,2, Lazzari M3,4, Carpenedo R4, Palombo E4, Silvi MB3,4, Mammucari M5, Dauri M3,4. Adv Ther. 2016 May 3. [Epub ahead of print]
Abstract：Oxycodone is one of the most commonly used opioid analgesics in the clinical management of pain. The present retrospective analysis aimed to determine the dose of oxycodone that could achieve effective control of moderate pain when combined with a fixed dose of acetaminophen, and the time required to reach a clinically relevant reduction in intensity of pain.
3.Removal of Acetaminophen-Protein Adducts by Autophagy Protects Against Acetaminophen-Induced Liver Injury in Mice.
Ni HM1, McGill MR1, Chao X1, Du K1, Williams JA1, Xie Y1, Jaeschke H1, Ding WX2. J Hepatol. 2016 May 2. pii: S0168-8278(16)30169-6. doi: 10.1016/j.jhep.2016.04.025. [Epub ahead of print]
BACKGROUND & AIMS: Acetaminophen (APAP)-induced liver injury is the most frequent cause of acute liver failure in the US and many other countries. Metabolism of APAP results in formation of APAP protein adducts (APAP-AD) in hepatocytes and triggers mitochondrial dysfunction and necrosis. However, the mechanisms for how APAP-AD are removed from hepatocytes remain unknown.
对不起，暂无产品评价！
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
怎么做细胞爬片免疫组化染色实验
细胞爬片免疫组化染色，是通过细胞爬片是让玻片浸在细胞培养基内，细胞在玻片上生长，主要用于组织学，免疫组织化学...
2020/7/20 22:04:33
提取病毒RNA的实验方法
提取病毒RNA方法分别有：异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
细胞培养耗材技术领先性
细胞培养板行业面临的核心痛点是：常规TC处理后表面亲水角随时间衰减，影响长期培养稳定性，BIOFOUNT高分...
2026/4/28 15:12:51
细胞培养耗材关键性能
细胞培养板的水接触角作为表面润湿性的核心指标，直接影响细胞贴壁、增殖、分化及功能表达，其中40°（低接触角/...
2026/4/28 14:52:44
chelex 100树脂国产替代之路-BIOFOUNT范德生物
Chelex 100螯合离子交换树脂对铜、铁和其他重金属?的偏好显著高于对钠、钾等一价阳离子的偏好。它对二价...
2025/11/4 14:22:46
9月开学季——助研新学期 范德送好礼
2025/8/28 15:30:55
Waxfilm 实验室封口膜：技术与国际市场的双重突破
在实验室耗材领域，封口膜是保障实验准确性与稳定性的关键产品之一。近年来，Waxfilm?实验室封口膜凭借其卓...
2025/5/13 13:03:40
Waxfilm实验室封口膜的5大突破
Waxfilm实验室封口膜作为生物功能膜领域的国产技术突破和品牌突破，是生物领域中国技术发展的缩影。
2025/5/6 17:02:07
各种微流控芯片键合方法的优缺点
微流控芯片键合：目前主要有激光焊接、热压键合、胶键合、超音波焊接，每种方法都有各自的优缺点。本文主要介绍聚酯...
2023/7/28 10:43:09
新一代微流控键合解决方案
微流控键合解决方案：微流控芯片制造的一个重要环节，也是最容易被忽视的--芯片键合。其中一个重要因素是：微流控...
2023/7/27 12:44:28
